MSMa Somsouk

Ma Somsouk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ma Somsouk has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • John M. Inadomi

    Department of Internal Medicine, The University of Utah School of Medicine, Salt Lake City, Utah, USA

    3 shared publications
  • Scott W. Biggins

    Department: Medicine, Division Gastroenterology and Hepatology, Institution: University of Colorado Health Sciences Center. Denver, CO

    2 shared publications
  • Claire Deleage

    AIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland

    1 shared publication
  • E. Vittinghoff

    Department: Epidemiology and Biostatistics Institution: University of California, San Francisco. San Francisco, CA

    1 shared publication
  • Eric Vittinghoff

    Department: Epidemiology and Biostatistics, Institution: University of California, San Francisco. San Francisco, CA

    1 shared publication
  • Hal F. Yee

    Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA USA

    1 shared publication

Latest Publications

  • Gut epithelial barrier and systemic inflammation during chronic HIV infection

    by Ma Somsouk, Jacob D. Estes, Claire Deleage, Richard M. Dunham, Rebecca Albright, John M. Inadomi, Jeffrey N. Martin, Steven G. Deeks, Joseph M. McCune, Peter W. Hunt

    Objective: Microbial translocation and innate immune action characterize HIV infection. Continued gut mucosal dysfunction during treatment and its relationship to CD4+ T-cell recovery has not been well described. Design: A cross-sectional study was performed of antiretroviral therapy (ART)-suppressed (immunologic responders with CD4+ > 500 cells/μl and immunologic nonresponders with CD4+ < 350 cells/μl), untreated HIV-infected, and seronegative participants consenting to gut biopsies and a blood draw. Methods: Neutrophil infiltration as a surrogate response to epithelial breach, colorectal epithelial proliferation as a measure of repair, and mucosal apoptosis by immunohistochemistry were determined in gut biopsies. Plasma markers of monocyte activation (sCD14), immune activation (interleukin-6), and indoleamine 2,3-dioxygenase-1 activity (plasma kynurenine/tryptophanratio) were concurrently measured. Results: Each HIV-infected group had greater neutrophil infiltration than controls. Similarly, untreated HIV-infected participants and ART-suppressed immunologic responders had increased epithelial proliferation compared with controls, but immunologic nonresponders had no appreciable increase in epithelial proliferation despite elevated neutrophil infiltration. The CD4+ T-cell count was positively correlated with epithelial proliferation and was modestly negatively correlated with neutrophil infiltration in ART-suppressed patients. Epithelial proliferation was inversely correlated with mucosal apoptosis, and apoptosis was linked to plasma sCD14 and modestly to kynurenine/tryptophan ratio. Conclusions: Neutrophil infiltration and mucosal apoptosis remain abnormally high despite ART. Epithelial proliferation increases in HIV, but may be impaired in immunologic nonresponders. Whether mucosal apoptosis is a cause or consequence of epithelial proliferative defects is unclear, but appears to be associated with systemic inflammation. The impact of ART and interventions targeting the gut epithelial barrier in treated HIV infection warrant further investigation.


  • Open Access

    Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk

    by Ma Somsouk, Rachel Kornfield, Eric Vittinghoff, John M. Inadomi, Scott W. Biggins

    Donor livers are offered to patients with the highest risk of death. How ascites could inform risk models to reduce liver transplant wait-list mortality is unclear. All adult candidates for primary liver transplantation for cirrhosis without exception points who were registered with the Organ Procurement and Transplantation Network from 2005 to 2007 composed our study cohort. Using Cox models and advanced discriminative metrics and paying attention to geographic disparities, we evaluated the additional risk discrimination of moderate ascites over that of the Model for End-Stage Liver Disease (MELD) or the Model for End-Stage Liver Disease plus serum sodium (MELD-Na) alone for the prediction of 90-day wait-list mortality. Additional analyses examined lower mortality risk candidates and those listed in high-demand, low-supply United Network for Organ Sharing regions in which accounting for ascites may most significantly affect wait-list mortality. Between 2005 and 2007, 18,124 subjects were listed for liver transplantation. Mortality was higher in patients with moderate ascites (15.4% versus 6.0%, P < 0.0001), and this risk persisted despite adjustments for MELD (hazard ratio = 1.58, 95% confidence interval = 1.42-1.76) and MELD-Na (hazard ratio = 1.42, 95% confidence interval = 1.28-1.58). The effect of moderate ascites was more prominent with a MELD score P < 0.01). With the addition of moderate ascites, there was improvement in the overall risk model, particularly with a MELD score <21, as measured by the C index and integrated discrimination improvement. Moderate ascites informed risk prediction, particularly with a MELD score <21 and in high-demand, limited-supply regions. Under the MELD system, the presence of moderate ascites should prompt clinicians to consider strategies to expand access to transplantation, such as the use of extended donor liver grafts. Liver Transpl 17:129–136, 2011. © 2011 AASLD.


  • Open Access

    Ascites improves upon plus serum sodium model for end‐stage liver disease (MELD) for predicting mortality in patients with advanced liver disease

    by M. Somsouk, J. Guy, S. W. Biggins, E. Vittinghoff, M. A. Kohn, J. M. Inadomi

    Summary: Background  The clinical impact of ascites has historically been well recognized; however, its value is unclear in the context of current prognostic models.Aim  To determine whether ascites can improve risk discrimination beyond model for end‐stage liver disease (MELD) and serum sodium (MELDNa).Methods  Consecutive cirrhotic patients were evaluated for ascites on the basis of an outpatient CT along with concurrent MELD and Na values. Cox models were used to determine the added value of ascites for predicting 1‐year mortality. Increases in the C‐index, integrated discrimination improvement (IDI) and the net reclassification index (NRI) were used to assess improvements in discrimination after the addition of ascites.Results  A total of 1003 patients had Na and MELD scores available within 30 days of the CT scan. A total of 60 deaths occurred within 1 year, with mortality higher in patients with ascites (21.4% vs. 4.0%, HR 6.08, 95% CI 3.62–10.19, P < 0.0005). In the presence of ascites, the MELD and MELDNa scores underestimated mortality risk when the scores were less than 21. The addition of ascites to the MELDNa model substantially improved discrimination by the C‐index (0.804 vs. 0.770, increase of 3.4%, 95% CI 0.2–9.9%), IDI (1.8%, P = 0.016) and NRI (15.8%, P = 0.0006).Conclusion  The incorporation of radiographic ascites significantly improves upon MELDNa for predicting 1‐year mortality. The presence of ascites may help identify patients at increased risk for mortality, not otherwise captured by either MELD or MELDNa.


  • Open Access

    Understanding Liver Health Using the National Center for Health Statistics

    by Ma Somsouk, Hal F. Yee, Scott W. Biggins

    The National Center for Health Statistics (NCHS) is the principal health statistics agency for the United States. It seeks to provide accurate, relevant, and timely data on health status and utilization of health care. As such, the NCHS represents a tremendous repository of behavioral, biological, and clinical data that can be employed to identify issues and effect change in public policy related to liver health and disease. By providing an understanding of the rich, publicly available data systems within the NCHS, investigators may capitalize on an efficient means to shape current knowledge of liver disease.